Berkeley Heights, NJ - October 17, 2003
- Genta Incorporated (Nasdaq: GNTA) announced today that it will
present at the Rodman & Renshaw Techvest Healthcare Conference
on Wednesday, October 22, 2003 at 9:40 a.m. EST. Dr. Raymond P.
Warrell, Jr., Genta's Chief Executive Officer, will provide an
update on the Company's late stage-products and development
programs.
A live audio webcast of the presentation can be accessed through
Genta's Investor Relations site at:
http://www.genta.com/genta/InvestorRelation/events.html
. A replay will be available for 90 days following the
presentation.
About Genta
Genta Incorporated is a biopharmaceutical company with a
diversified product portfolio that is focused on delivering
innovative products for the treatment of patients with cancer. The
Company's research platform is anchored by two major programs that
center on DNA/RNAbased medicines and small molecules. Genasense
TM
(oblimersen sodium) is the Company's lead compound from its
oligonucleotide program and is currently undergoing late-stage,
Phase 3 clinical testing. The leading drug in Genta's small
molecule program is Ganite
TM
(gallium nitrate injection), whic h is approved for the treatment
of cancer-related hypercalcemia that is resistant to hydration and
is being exclusively marketed by Genta in the US. For more
information about Genta, please visit our website at:
http://www.genta.com/
.
This press release and the webcast to follow contain
forward-looking statements with respect to business conducted by
Genta Incorporated. By their nature, forward-looking statements and
forecasts involve risks and uncertainties because they relate to
events and depend on circumstances that will occur in the future.
There are a number of factors that could cause actual results and
developments to differ materially. For a discussion of those risks
and uncertainties, please see the Company's Annual
Report/Form 10-K
for 2002
.
SOURCE: Genta Incorporated
